A novel bispecific T-cell engager(BiTE)has been developed as an efficient immunotherapeutic molecule specifically bringing the T-cell and the tumor target together for enhanced immunotherapy.The general BiTE construct consists of two single-chain variable antibody fragments(scFvs)targeting a tumor-...
A nanobody-guided multifunctional T cell engager promotes strong anti-tumor responses via synergistic immuno-photothermal effects Shenxia Xie Wei Shi Xiaoling Lu Journal of Nanobiotechnology(2024) Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances ...
LAVA-1207Bispecific T cell engager antibodyGCP2, PSMA, TCR• Hormone-resistant prostate cancer • Solid tumorPhase 2 Recommended Services Anti-idiotype Antibody Production Services Nanobody Development and Production Platform Nanobodies are very promising next-generation therapeutic antibodies that have ...
scFv modules in turn can be fused to one another, e.g., to generate a bispecific T-cell engager, or they can be fused in various orientations to antibody hinge and Fc domains to generate bi- and multispecific antibodies. However, the inherent hydrophobic interaction of VH and VL domains ...
T cell engager (Nb-TriTE) would be a potential strategy to improve therapeutic efficacy.#Given the therapeutic potential of nanobodies (Nbs), we first screened Nb targeting fibroblast activation protein (FAP) and successfully generated a Nb-based bispecific T cell engager (Nb-BiTE) targeting FAP...